Non-Melanoma Skin Cancer Market is projected to further expand, reaching up to USD 911.9 million by 2030

Report Overview
The Global Non-Melanoma Skin Cancer Market has exhibited substantial growth, reaching USD 645.7 million in 2022 and is projected to further expand, reaching up to USD 911.9 million by 2030. The market is anticipated to experience a Compound Annual Growth Rate (CAGR) of 4.5% during the forecast period from 2023 to 2030.

Non-melanoma skin cancers, which generally develop in the skin's outermost layer (epidermis), are named after the specific type of skin cell from which they originate. Basal cell carcinoma (BCC), also known as a rodent ulcer, initiates in the cells lining the bottom of the epidermis and constitutes approximately 75 out of every 100 skin malignancies. Squamous cell carcinoma (SCC), originating in the cells lining the top of the epidermis, accounts for around 20 percent of all skin malignancies.

The market's robust growth can be attributed to various factors, including the innovation of new products, an increase in the number of clinical trials, rising demand for products, and surging healthcare expenditure. These factors collectively contribute to the expanding size and opportunities within the non-melanoma skin cancer market.

Download a Free PDF Sample - https://www.datamintelligence.com/download-sample/non-melanoma-skin-cancer-market

Market Dynamics
The rising geriatric population across the globe is a significant contributing factor to the prevalence of non-melanoma skin cancer (NMSC), which includes squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Age is a substantial risk factor for various types of skin cancer, and NMSC is no exception. It is the most common form of cancer worldwide, and its incidence is notably higher among older individuals.

Several factors contribute to the increased risk of non-melanoma skin cancer in the elderly population. Prolonged exposure to the sun over a person's lifetime, fair skin, a history of sunburns, a compromised immune system, exposure to certain chemicals or radiation, and a family history of skin cancer are all recognized risk factors. Older individuals often have accumulated more sun exposure throughout their lives, making them more vulnerable to developing non-melanoma skin cancer.

For instance, statistics from the Skin Cancer Foundation highlight the prevalence of skin cancer in the United States. With 1 in 5 Americans projected to develop skin cancer by the age of 70, the impact of skin cancer on the aging population is significant. Detecting skin cancer early is crucial, as reflected in the high 5-year survival rate of 99% for melanoma when diagnosed at an early stage. The rising geriatric population worldwide emphasizes the importance of addressing and managing the risks associated with non-melanoma skin cancer.

For more detailed information - https://www.datamintelligence.com/research-report/non-melanoma-skin-cancer-market

Market Segmentation
By Treatment
Immunotherapy
Radiation Therapy
Chemotherapy
Photodynamic Therapy
Others

By Indication
Basal cell carcinoma
Squamous cell carcinoma.
T Cell Lymphoma

By End User
Hospitals
Ambulatory surgical centers
Speciality Clinics

Market Key Players
Major players are Merck and Co Inc, Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann La Roche AG and Novartis AG, and Amgen.

Trending Reports
Skin Cancer Market - https://www.datamintelligence.com/research-report/skin-cancer-market

Radiodermatitis Market - https://www.datamintelligence.com/research-report/radiodermatitis-market

Skin Cancer Drugs Market - https://www.datamintelligence.com/research-report/skin-cancer-drugs-market

Contact Us:
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence:
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.